Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

NCT02175784 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02175784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2014
Completion date
December 7, 2015
Enrollment
262 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus